{
  "ticker": "IMC",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02972663",
  "id": "02972663",
  "pages": 19,
  "price_sensitive": false,
  "date": "20250725",
  "time": "0942",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250725/pdf/06m49k6f6fxf1f.pdf",
  "summary": "No material information identified.  \n\n*Note: The document is a corporate presentation announcement for an investor conference, containing forward-looking statements and business updates, but no immediate trading or capital markets triggers (e.g., no new capital raising, financial results, or material corporate actions).*  \n\nIf specific data points like revenue figures or clinical trial updates are needed for analysis, highlight:  \n- FY2025 unaudited revenue: A$7.3M (+49% YoY).  \n- North America sales: A$2.0M (+76% YoY).  \n- Cash balance (Dec 2024): A$7.7M.  \n- Key milestone: IMM-529 IND submission targeted by September 2025.",
  "usage": {
    "prompt_tokens": 7331,
    "completion_tokens": 149,
    "total_tokens": 7480,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-24T23:55:11.877735"
}